Human Pharmaceutical Products — Revenue
Eli Lilly Human Pharmaceutical Products — Revenue increased by 2.6% to $19.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.5%, from $12.73B to $19.80B. Over 4 years (FY 2021 to FY 2025), Human Pharmaceutical Products — Revenue shows an upward trend with a 23.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong commercial adoption, successful product launches, or expanded market share for the company's drug portfolio. A decrease may signal increased generic competition, patent expirations, or challenges in product supply and demand.
Detailed definition
This metric represents the total net sales generated from the company's portfolio of pharmaceutical products intended fo...
Peer comparison
This is a standard top-line revenue metric for pharmaceutical companies, comparable to 'Total Pharmaceutical Sales' or 'Human Health Revenue' reported by major global peers.
lly_segment_human_pharmaceutical_products_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.74B | $6.77B | $8.00B | $7.81B | $6.49B | $6.94B | $7.30B | $6.96B | $8.31B | $9.50B | $9.35B | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| QoQ Change | — | +0.5% | +18.1% | -2.4% | -16.9% | +7.0% | +5.2% | -4.7% | +19.4% | +14.3% | -1.5% | -6.3% | +28.9% | +1.2% | +18.3% | -5.9% | +22.2% | +13.1% | +9.6% | +2.6% |
| YoY Change | — | — | — | — | -3.7% | +2.5% | -8.7% | -10.9% | +28.1% | +36.8% | +28.1% | +26.0% | +36.0% | +20.4% | +44.7% | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's human pharmaceutical products — revenue?
- Eli Lilly (LLY) reported human pharmaceutical products — revenue of $19.80B in Q1 2026.
- How has Eli Lilly's human pharmaceutical products — revenue changed year-over-year?
- Eli Lilly's human pharmaceutical products — revenue increased by 55.5% year-over-year, from $12.73B to $19.80B.
- What is the long-term trend for Eli Lilly's human pharmaceutical products — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's human pharmaceutical products — revenue has grown at a 23.2% compound annual growth rate (CAGR), from $28.32B to $65.18B.
- What does human pharmaceutical products — revenue mean?
- The total revenue earned from selling pharmaceutical drugs designed for human patients.